Precision memory endpoints for the prodromal treatment window
Amnestic MCI represents the clinical stage where memory impairment is objectively measurable but daily function remains intact. This is the primary treatment window for disease-modifying therapies, and trial endpoints need sufficient sensitivity to detect stabilization or slowed decline over 12-18 month intervals.
The aMCI Endpoint Problem
Current aMCI trials rely on ADAS-Cog and CDR-SB as primary endpoints. These instruments were designed for moderate dementia and show ceiling effects in MCI populations. ADAS-Cog has a standardized response mean (SRM) of 0.3-0.5 in aMCI treatment trials, requiring 200+ subjects per arm for adequate power. Many trials that showed biological target engagement failed to demonstrate cognitive benefit because the endpoint lacked sensitivity, not because the therapy lacked efficacy.
Why Consolidation Matters for aMCI
In aMCI, hippocampal atrophy is already measurable on MRI, and the memory consolidation system is actively degrading. FNAME subtests correlate with frontal amyloid-beta deposition in this population, linking consolidation performance to core disease pathology. Overnight forgetting rates provide a more granular and sensitive signal than 30-minute delayed recall, where many aMCI patients already show impairment but lack room for further measurable decline.
Published Evidence
Research supporting consolidation-based endpoints for amnestic mild cognitive impairment assessment.
FNAME Predicts Alzheimer Progression
Face-name associative memory performance correlates with amyloid burden and predicts conversion from MCI to Alzheimer dementia. The ARMADA study ranked FNAME first among 61 cognitive measures for prognostic sensitivity.
Rentz DM, et al. Alzheimers Dement, 2022 (ARMADA study)
Consolidation Deficits Scale with Disease Severity
Overnight forgetting rates increase progressively from cognitively normal to aMCI to mild AD, providing a continuous measurement axis across the disease spectrum rather than the categorical cutoffs used by standard scales.
Walsh CM, et al. Neurobiology of Aging, 2014
Hippocampal-Neocortical Transfer Disruption
fMRI studies demonstrate that aMCI patients show reduced hippocampal-cortical connectivity during sleep, directly impairing the systems consolidation process that FaceWise is designed to measure.
Published neuroimaging literature on MCI sleep architecture
Trial Applications
Clinical trial contexts where FaceWise consolidation endpoints add value for amnestic mild cognitive impairment programs.
Ready to discuss amnestic mild cognitive impairment endpoints?
Schedule a consultation to explore how FaceWise consolidation endpoints can strengthen your amnestic mild cognitive impairment clinical program.